ATR Isomerization in Cellular Responses to UV Damage of DNA
细胞对 DNA 紫外线损伤反应中的 ATR 异构化
基本信息
- 批准号:10220898
- 负责人:
- 金额:$ 35.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:ATR geneAddressAdoptedAgingAmino AcidsApoptosisApoptoticBCL2 geneCancer BiologyCardiovascular DiseasesCell Cycle ProgressionCell DeathCell NucleusCell SurvivalCellsClinicClinical TrialsComplexCytoplasmDNADNA DamageDNA RepairDNA damage checkpointEmbryoExhibitsFamilyFamily memberHumanIsomerismKRP proteinKnock-outLaboratoriesMalignant NeoplasmsMalignant neoplasm of ovaryMapsMass Spectrum AnalysisMediatingMitochondriaMolecular ConformationMutant Strains MiceMutateNIMANeurodegenerative DisordersNuclearOrganellesPathway interactionsPhosphatidylinositolsPhosphorylationPhosphotransferasesPlayPost-Translational Protein ProcessingProtein DephosphorylationProtein FamilyProtein FootprintingProtein KinaseProteinsRoleSignal TransductionStructureStructure-Activity RelationshipStudy modelsTREX1 geneTelangiectasisTestingUV carcinogenesisUV inducedUV induced DNA damageataxia telangiectasia mutated proteinbasecancer preventioncancer therapycarcinogenesiscis trans isomerizationcis-trans-Isomerasescytochrome cepidemiology studygenome integrityhuman diseasein vivoinnovationmembermouse modelnovelnovel strategiesprotein functionresponsetherapeutic targettumorigenesisultraviolet damage
项目摘要
Summary
DNA damage is a major cause of human cancers and many other human diseases. In response to
DNA damage, cells activate DNA damage response (DDR) pathways such as DNA damage checkpoints,
DNA repair, and apoptosis. ATR (ataxia telangiectasia and Rad3-related), a member of the
phosphoinositide 3-kinase-related protein kinases (PIKK) family, is a major DNA damage checkpoint
protein kinase which plays a critical role in DDR by signaling DNA damage, activating checkpoints,
arresting cell cycle progression and facilitating DNA repair to restore DNA integrity. Interestingly, a body
of evidence from mouse model and human epidemiologic studies shows that unlike ATM, a closely related
ATR-like PIKK family member whose deficiency promotes carcinogenesis, ATR inhibition suppresses
carcinogenesis. Moreover, ATR knockout is embryonically lethal. These suggest an involvement of ATR
in regulating cell death. Although ATR has been extensively studied as a checkpoint kinase in DDR in the
nucleus, little is known about its functions in the cytoplasm or mitochondria, the cellular organelle for
activating DNA damage-induced apoptosis. A recent finding from the P.I.’s lab reveals that (a) besides its
hallmark nuclear checkpoint functions, ATR is a pro-survival protein functioning directly at mitochondria
against UV damage; (b) ATR contains a BH3-like domain that allows ATR to act like a Bcl-2 family protein;
(c) importantly, mitochondrial ATR is a prolyl cis-isomeric form of ATR regulated by Pin1 while in contrast,
nuclear ATR is a trans-isomeric form of ATR; and finally (d) mitochondria activity of ATR is independent of
its checkpoint kinase activity and ATRIP. In this project, we will test the hypotheses that (1) Prolyl
isomerization alters the structure of ATR, transforming ATR functions for mitochondria-specific activities to
promote cell survival or nuclear functions as a DNA damage checkpoint regulator; (2) Antiapoptotic activity
of ATR at mitochondria plays an important role in mediating carcinogenesis in vivo, and thus, suppressing
such activity may reduce carcinogenesis/tumorigenesis and provide a strategy for cancer prevention and
treatment; and (3) ATR’s trans-isomeric form is required for its DNA damage checkpoint activity, and post-
translational modifications of ATR and/or ATR-ATRIP complex formation may play a role in stabilizing ATR
in the trans-isomeric form in the nucleus. These hypotheses will be tested in the following specific aims.
Aim 1: To define the structure-function relationships of ATR prolyl isomers, and of ATRH-tBid and ATRH-
Pin1 interactions; Aim 2: To determine the role of prolyl isomerization in the nuclear functions of ATR; and
Aim 3: To determine the in vivo effects of ATR isomers on carcinogenesis and tumorigenesis. The
proposed studies represent an innovative effort highly relevant to cancer biology and also having
implications in other human diseases such as neurodegenerative and cardiovascular diseases.
概括
DNA 损伤是人类癌症和许多其他人类疾病的主要原因。作为回应
DNA损伤,细胞激活DNA损伤反应(DDR)途径,例如DNA损伤检查点,
DNA 修复和细胞凋亡。 ATR(毛细血管扩张性共济失调和 Rad3 相关),
磷酸肌醇 3 激酶相关蛋白激酶 (PIKK) 家族是主要的 DNA 损伤检查点
蛋白激酶通过发出 DNA 损伤信号、激活检查点,在 DDR 中发挥关键作用,
阻止细胞周期进程并促进 DNA 修复以恢复 DNA 完整性。有趣的是,一个身体
来自小鼠模型和人类流行病学研究的证据表明,与 ATM 不同,一种密切相关的
ATR 样 PIKK 家族成员,其缺陷促进致癌,ATR 抑制抑制
致癌作用。此外,ATR 敲除具有胚胎致死性。这些表明 ATR 的参与
调节细胞死亡。尽管 ATR 作为 DDR 中的检查点激酶已被广泛研究
细胞核,但对其在细胞质或线粒体(细胞器)中的功能知之甚少。
激活DNA损伤诱导的细胞凋亡。 P.I. 实验室最近的一项发现表明,(a) 除了
ATR 是一种标志性核检查点功能,是一种直接在线粒体上发挥作用的促生存蛋白
防止紫外线伤害; (b) ATR 含有 BH3 样结构域,使 ATR 能够像 Bcl-2 家族蛋白一样发挥作用;
(c) 重要的是,线粒体 ATR 是 ATR 的脯氨酰顺式异构形式,受 Pin1 调节,而相比之下,
核ATR是ATR的反式异构形式;最后 (d) ATR 的线粒体活性独立于
其检查点激酶活性和 ATRIP。在这个项目中,我们将测试以下假设:(1) Prolyl
异构化改变了 ATR 的结构,将线粒体特异性活动的 ATR 功能转变为
作为 DNA 损伤检查点调节剂促进细胞存活或核功能; (2) 抗凋亡活性
线粒体上的 ATR 在介导体内致癌过程中发挥重要作用,从而抑制
这种活性可能会减少癌变/肿瘤发生,并为癌症预防和治疗提供策略。
治疗; (3) ATR 的反式异构体形式是其 DNA 损伤检查点活性所必需的,并且后
ATR 和/或 ATR-ATRIP 复合物形成的翻译修饰可能在稳定 ATR 中发挥作用
在细胞核中以反式异构体形式存在。这些假设将在以下具体目标中得到检验。
目标 1:定义 ATR 脯氨酰异构体、ATRH-tBid 和 ATRH- 的结构-功能关系
Pin1 交互;目标2:确定脯氨酰异构化在ATR核功能中的作用;和
目标 3:确定 ATR 异构体对癌发生和肿瘤发生的体内影响。这
拟议的研究代表了与癌症生物学高度相关的创新努力,并且还具有
对神经退行性疾病和心血管疾病等其他人类疾病的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yue Zou其他文献
Yue Zou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yue Zou', 18)}}的其他基金
ATR Isomerization in Cellular Responses to UV Damage of DNA
细胞对 DNA 紫外线损伤反应中的 ATR 异构化
- 批准号:
9361724 - 财政年份:2017
- 资助金额:
$ 35.34万 - 项目类别:
ATR Isomerization in Cellular Responses to UV Damage of DNA
细胞对 DNA 紫外线损伤反应中的 ATR 异构化
- 批准号:
10459421 - 财政年份:2017
- 资助金额:
$ 35.34万 - 项目类别:
ATR Isomerization in Cellular Responses to UV Damage of DNA
细胞对 DNA 紫外线损伤反应中的 ATR 异构化
- 批准号:
10012775 - 财政年份:2017
- 资助金额:
$ 35.34万 - 项目类别:
Antiapoptotic Role of Ataxia Telangiectasia and Rad3-Related
共济失调毛细血管扩张症和 Rad3 相关的抗凋亡作用
- 批准号:
9263097 - 财政年份:2014
- 资助金额:
$ 35.34万 - 项目类别:
Antiapoptotic Role of Ataxia Telangiectasia and Rad3-Related
共济失调毛细血管扩张症和 Rad3 相关的抗凋亡作用
- 批准号:
8770880 - 财政年份:2014
- 资助金额:
$ 35.34万 - 项目类别:
Biochemical Insight of Hyperphosphorylation of Replication Protein A
复制蛋白 A 过度磷酸化的生化见解
- 批准号:
8005163 - 财政年份:2010
- 资助金额:
$ 35.34万 - 项目类别:
Mechanism of Nuclear Defects in Hutchinson-Gilford Progeria Syndrome
哈钦森-吉尔福德早衰综合症的核缺陷机制
- 批准号:
7472794 - 财政年份:2008
- 资助金额:
$ 35.34万 - 项目类别:
Biochemical Insight of Hyperphosphorylation of Replication Protein A
复制蛋白 A 过度磷酸化的生化见解
- 批准号:
7365510 - 财政年份:2008
- 资助金额:
$ 35.34万 - 项目类别:
Mechanism of Nuclear Defects in Hutchinson-Gilford Progeria Syndrome
哈钦森-吉尔福德早衰综合症的核缺陷机制
- 批准号:
7576814 - 财政年份:2008
- 资助金额:
$ 35.34万 - 项目类别:
RECOGNITION AND REPAIR OF UV DAMAGE TO HUMAN DNA
人类 DNA 紫外线损伤的识别和修复
- 批准号:
6377972 - 财政年份:2000
- 资助金额:
$ 35.34万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.34万 - 项目类别:
Research Grant














{{item.name}}会员




